TNF and colitis: The monoclonal antibodies targeting M1-associated cytokines TNF-α, including infliximab and adalimumab, have been approved to treat moderate to severe colitis in clinic (39, 40), while patients with the M2-related factor IL-10 receptor deficiency have enhanced susceptibility to severe colitis (41).